EQT seeks to acquire Qiagen for €9.6 billion
The private-equity group is offering €46.50 per share for the diagnostics company from Venlo.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
Swedish investor EQT wants to acquire Dutch-German molecular diagnostics company Qiagen for approximately €9.6 billion. Qiagen’s management supports the offer, which is expected to be completed in mid-2027.
EQT and Qiagen announced on Wednesday that they had reached an agreement on a voluntary cash offer. EQT is offering shareholders €46.50 per share. According to Reuters, this represents a premium of 8.6 per cent over the closing price before the announcement.
According to its company information, Qiagen has its legal seat in Venlo and develops equipment, tests and analytical technology for genetic material. The company supplies research laboratories and the healthcare sector. According to information previously provided by the company, Qiagen had approximately 5,500 employees at more than 35 locations as at 30 June.
According to Reuters, the transaction values Qiagen at approximately $10.8 billion, including around $1.1 billion in net debt. EQT says it will finance the acquisition with equity and debt financing. According to the joint announcement, funds from the Abu Dhabi Investment Authority and the Canada Pension Plan Investment Board are also participating in the offer.
Under the agreement, Qiagen will continue to operate under its own name and brand. The board of directors has recommended the offer. Shareholders still have to approve it, and other customary conditions must also be fulfilled. Completion is expected in mid-2027, according to Reuters.
Qiagen also suspended its full-year 2026 outlook pending the transaction. The company reported preliminary third-quarter revenue of $548 million and adjusted earnings per share of $0.65. These are preliminary quarterly figures; on their own, they say nothing yet about the consequences of the acquisition for employees, sites or customers.
The acquisition is relevant to the Netherlands because Qiagen is an important company in Venlo, but the business operates internationally. It is not yet known whether the change in ownership will lead to changes in its Dutch operations. The announcements currently available contain no concrete commitments on this matter.
Also show where in Europe and in the world
One story, several perspectives
What is established
- EQT has made a recommended offer of €46.50 per share for Qiagen.
- Qiagen has its legal base in Venlo and operates internationally in molecular diagnostics.
- Shareholders still have to vote on the offer; the consequences for employees and sites are not yet known.
Left
Arguments A company that supplies crucial diagnostics should not be judged solely on returns for shareholders. Employees, public healthcare and long-term investment deserve firm safeguards in a private-equity takeover.
Values The public interest, job security, and continuity of healthcare and research.
Consequences More conditions could protect jobs and investment, but could delay a takeover or reduce the price for shareholders.
Centre
Arguments A takeover can provide capital and focus, as long as competition rules, the works council and shareholders retain their roles. The proper assessment depends on the financing, the strategy and concrete agreements about the operations.
Values Institutional diligence, market forces and continuity.
Consequences A careful process can leave room for both efficiency and protection, but it will only provide clarity about the practical outcome later.
Right
Arguments Private equity can make a company more agile and offer shareholders an attractive price. The government should exercise restraint as long as there is no demonstrable threat to the market or national security.
Values Freedom of ownership, entrepreneurship and returns.
Consequences Less political interference can speed up transactions and investment, but leaves more uncertainty about future decisions under the new ownership.
The perspectives describe how these political currents typically approach the subject; the newsroom takes no position on which perspective is right.
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The financial core and the announced conditions were confirmed by the company announcement and a Reuters report. Uncertain consequences for employees and operations have explicitly been presented as unknown.
- confirmed EQT is offering €46.50 per Qiagen share. — Mentioned in the company announcement and by Reuters. source
- confirmed The transaction amounts to approximately €9.6 billion. — The company announcement and Reuters cite this valuation. source
- confirmed Qiagen has approximately 5,500 employees. — Qiagen states this in its company information. source
- confirmed The acquisition is expected to be completed in mid-2027. — Reuters cites this expectation. source
- confirmed Qiagen suspended its outlook for 2026. — Reuters reports this based on the company announcement. source
Editor's note
The offer, price, board support, financing and preliminary figures were reported by Qiagen/EQT and Reuters. The consequences for employees, sites and customers remain unknown and have therefore not been presented as fact.Sources
- QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer — EQT via PR Newswire
- EQT to buy molecular testing firm Qiagen for $10.8 billion — Reuters via MarketScreener